William Jacob Savage - 15 Dec 2025 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Chief Medical Officer
Signature
By: /s/ Rahul Khara, as Attorney-in-Fact
Issuer symbol
IRON
Transactions as of
15 Dec 2025
Net transactions value
-$1,194,372
Form type
4
Filing time
16 Dec 2025, 21:31:58 UTC
Previous filing
01 Jul 2025
Next filing
29 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Savage William Jacob Chief Medical Officer C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN By: /s/ Rahul Khara, as Attorney-in-Fact 16 Dec 2025 0001951852

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Sale $329,979 -3,642 -4.1% $90.60 85,153 15 Dec 2025 Direct F1, F2
transaction IRON Common Stock Sale $836,724 -9,151 -11% $91.44 76,002 15 Dec 2025 Direct F1, F3
transaction IRON Common Stock Sale $27,669 -300 -0.39% $92.23 75,702 15 Dec 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.02 to $90.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.03 to $91.99, inclusive.